[go: up one dir, main page]

TR199701666A2 - Sismanliga karsi proteinler - Google Patents

Sismanliga karsi proteinler

Info

Publication number
TR199701666A2
TR199701666A2 TR97/01666A TR9701666A TR199701666A2 TR 199701666 A2 TR199701666 A2 TR 199701666A2 TR 97/01666 A TR97/01666 A TR 97/01666A TR 9701666 A TR9701666 A TR 9701666A TR 199701666 A2 TR199701666 A2 TR 199701666A2
Authority
TR
Turkey
Prior art keywords
proteins
grass proteins
allow
grass
handicap
Prior art date
Application number
TR97/01666A
Other languages
English (en)
Other versions
TR199701666A3 (tr
Inventor
Michael Beals John
Eugene Chance Ronald
Arthur Hoffman James
Lee Millican Rohn
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR199701666A2 publication Critical patent/TR199701666A2/tr
Publication of TR199701666A3 publication Critical patent/TR199701666A3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bu bulus, biyolojik olarak aktif sismanlik proteinleri temin etmektedir. Bu maddeler, hastalarin sismanlik handikaplarini yenmelerine olanak vermekte ve tip 2 seker hastaligi, kardiyovaskular hastalik ve kanser için daha normallesmis bir risk ile yasamalarini saglamaktadir.
TR97/01666A 1996-12-20 1997-12-19 Sismanliga karsi proteinler TR199701666A3 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3356196P 1996-12-20 1996-12-20

Publications (2)

Publication Number Publication Date
TR199701666A2 true TR199701666A2 (tr) 1999-10-21
TR199701666A3 TR199701666A3 (tr) 1999-10-21

Family

ID=21871119

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/01666A TR199701666A3 (tr) 1996-12-20 1997-12-19 Sismanliga karsi proteinler

Country Status (23)

Country Link
EP (1) EP0849276A1 (tr)
JP (1) JPH10179158A (tr)
KR (1) KR19980064258A (tr)
CN (1) CN1194986A (tr)
AR (1) AR013886A1 (tr)
AU (2) AU4843297A (tr)
BR (1) BR9706358A (tr)
CA (1) CA2217698A1 (tr)
CO (1) CO4700343A1 (tr)
CZ (1) CZ407097A3 (tr)
HU (1) HUP9702500A3 (tr)
ID (1) ID19257A (tr)
IL (1) IL122569A0 (tr)
NO (1) NO975938L (tr)
NZ (1) NZ329413A (tr)
PE (1) PE47599A1 (tr)
PL (1) PL323956A1 (tr)
SG (1) SG65040A1 (tr)
SV (1) SV1997000107A (tr)
TR (1) TR199701666A3 (tr)
WO (1) WO1998028335A1 (tr)
YU (1) YU48997A (tr)
ZA (1) ZA9710877B (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808593A (pt) 1997-04-15 2000-05-23 Csir Composições farmacêuticas com atividade supressora do apetite
WO1999044598A2 (en) * 1998-03-03 1999-09-10 Board Of Regents, The University Of Texas System Methods for inhibiting βcell apoptosis
GB9924484D0 (en) * 1999-10-15 1999-12-15 Isis Innovation Altered polypeptide aggregation
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
JP5031827B2 (ja) 2006-06-01 2012-09-26 程云 予防或いは肝損傷を治療するペプチッド
US12466883B1 (en) * 2024-05-13 2025-11-11 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5827734A (en) * 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
CA2211664A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
AU4862396A (en) * 1995-02-06 1996-08-27 Eli Lilly And Company Human obesity gene
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
AU6284896A (en) * 1995-06-22 1997-01-22 Eli Lilly And Company Obesity protein intermediates and their preparation and use

Also Published As

Publication number Publication date
EP0849276A1 (en) 1998-06-24
SV1997000107A (es) 1999-01-18
NO975938D0 (no) 1997-12-17
JPH10179158A (ja) 1998-07-07
AU5384698A (en) 1998-07-17
TR199701666A3 (tr) 1999-10-21
CA2217698A1 (en) 1998-06-20
SG65040A1 (en) 1999-05-25
HUP9702500A3 (en) 1999-07-28
KR19980064258A (ko) 1998-10-07
WO1998028335A1 (en) 1998-07-02
ZA9710877B (en) 1999-06-03
HUP9702500A2 (hu) 1998-07-28
BR9706358A (pt) 1999-05-04
YU48997A (sh) 1999-09-27
AU4843297A (en) 1998-06-25
HU9702500D0 (en) 1998-03-02
CN1194986A (zh) 1998-10-07
NZ329413A (en) 1999-10-28
AR013886A1 (es) 2001-01-31
ID19257A (id) 1998-06-28
NO975938L (no) 1998-06-22
IL122569A0 (en) 1998-06-15
CO4700343A1 (es) 1998-12-29
PL323956A1 (en) 1998-06-22
CZ407097A3 (cs) 1998-07-15
PE47599A1 (es) 1999-05-14

Similar Documents

Publication Publication Date Title
ES2183351T3 (es) Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.
EP1196444B8 (en) Exendin-4 conjugates and their medical use
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
DE69736634D1 (de) Antagonisten des intestinotrophen glp-2 peptides
TR200003161T2 (tr) Poliol-IFN-Beta konjugatları
ATE343969T1 (de) Beschichtete medizinische geräte
DE69032679D1 (de) Threo (2R, 3S)-3-amino-2-hydroxypentansäure und threo (2R,3S)-3-(p-methoxy-benzyloxycarbonyl/FMOC) amino-2-hydroxy-pentansäure
DK0944396T3 (da) Præparater og fremgangsmåder til forøgelse af tarmfunktion
TR200103469T2 (tr) Amiloidojenik hastalığının önlenmesi ve tedavisi
DE69024965D1 (de) Dehydrodidemnin b
DE69937294D1 (de) Von cyclophilin b abstammende tumorantigen-peptide
PT927150E (pt) Compostos de lipoxina e sua utilizacao no tratamento de doencas proliferativas celulares
ATE267613T1 (de) Arzneimittel und deren verwendung
DK0749317T3 (da) Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
TR199800912T2 (tr) Tümör asisi ve asinin hazirlanmasi için usul.
TR199701666A2 (tr) Sismanliga karsi proteinler
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
RU95106680A (ru) Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
TR199800521T1 (tr) Seçimli beta3 adrenerjik agonistler.
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
EP1116791A4 (en) NEW TUMOR-ANTIGEN-PROTEIN SART-3 AND TUMOR-ANTIGEN-PEPTID OF IT
ATE319819T1 (de) Humane hirn-spezifische carboxypeptidase b